Clinical Evaluation of the Newly Formatted Lateral-Flow Device for Invasive Pulmonary Aspergillosis by Hoenigl, M et al.
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/myc.12704 
This article is protected by copyright. All rights reserved. 
DR MARTIN  HOENIGL (Orcid ID : 0000-0002-1653-2824) 
 
Article type      : Original Article 
 
Clinical Evaluation of the Newly Formatted Lateral-
Flow Device for Invasive Pulmonary Aspergillosis 
 
Running head: Newly formatted LFD for invasive aspergillosis 
 
Martin Hoenigl 1,2,3,4#, Susanne Eigl 1, Sven Heldt 1, Wiebke Duettmann 1, 
Christopher Thornton 5, Juergen Prattes 2,4#  
 
1  Division of Pulmonology, Medical University of Graz, Graz, Austria  
2 Section of Infectious Diseases and Tropical Medicine, Medical University of Graz, 
Graz, Austria 
3 Division of Infectious Diseases, Department of Medicine, University of California–
San Diego, San Diego, USA  
4 CBmed - Center for Biomarker Research in Medicine, Graz, Austria 
5 Biosciences, University of Exeter, Exeter, United Kingdom 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
# Corresponding authors:  
Martin Hoenigl, M.D., Section of Infectious Diseases and Tropical Medicine AND 
Division of Pulmonology, Department of Internal Medicine, 
Medical University of Graz, A- 8036 Graz, Austria. 
Phone: +43 316 385 81319 Fax: +43 316 385 14622 
E-mail: martin.hoenigl@medunigraz.at 
 
AND  
Juergen Prattes, M.D., Section of Infectious Diseases and Tropical Medicine, 
Department of Internal Medicine, 
Medical University of Graz, A- 8036 Graz, Austria. 
Phone: +43 316 385 30046 Fax: +43 316 385 14622 
E-mail: juergen.prattes@medunigraz.at 
 
Key words: Haematological malignancy, bronchoalveolar lavage, Galactomannan, 
ICU, point-of-care. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Abstract 
The study evaluated the newly formatted Aspergillus-specific lateral-flow-device 
(LFD), and compared its performance to the original prototype “old” LFD test using 
BALF samples from 28 patients (14 patients with probable/proven invasive 
pulmonary aspergillosis [IPA] and 14 patients with no evidence for IPA). A total of 
10/14 (71%) of BALF samples from patients with probable/proven IPA resulted 
positive with the new LFD, including 8/9 with true-positive and 2/5 with false-negative 
results with the old LFD. All 14 samples from patients without IPA resulted negative 
with the new LFD; specificity of the new LFD was significantly improved compared to 
the old LFD. 
 
Introduction 
Diagnosis of invasive pulmonary aspergillosis (IPA) during the early stages of 
disease enables targeted antifungal treatment and has the potential to significantly 
improve patient survival [1]. The Aspergillus-specific lateral-flow device (LFD) is an 
immuno-chromatographic assay that detects an extracellular glycoprotein antigen 
secreted during active growth of the pathogen [2]. The ease-of-use of the assay, 
requiring no pre-treatment of bronchoalveolar lavage fluid (BALF), allows point-of-
care testing, with results available within 15 minutes. To date, a prototype version of 
the test has been evaluated with more than 650 BALF samples across a number of 
studies, with an overall sensitivity of 73%, specificity of 90%, a positive predictive 
value (PPV) of 61%, and negative predictive value (NPV) of 94% for probable/proven 
IPA versus no IPA [3-9]. As with other diagnostic tests for IPA such as the 
galactomannan [GM] ELISA, LFD sensitivity is reduced by mould-active antifungal 
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drugs [10]. Despite this, it’s accuracy in detecting IPA in hematological malignancy 
patients with probable/proven disease has been demonstrated [3,6,11], with a 
specificity of 91% and sensitivity of 67%, and with additional discriminatory power for 
possible IPA, with 31% of cases negative by GM ELISA being positive by LFD [3].  
Following extensive appraisal of the prototype LFD, the test has now been formatted 
for large-scale manufacture and CE marking as an in vitro diagnostic (IVD) device. 
The objective of this study was to clinically evaluate the newly formatted (hereafter 
referred to as new) LFD for the first time, and to compare its performance against the 
prototype (hereafter referred to as old) LFD using BALF samples from hematological 
malignancy and intensive care unit (ICU) patients.   
 
Methods: 
This study was conducted at the Medical University of Graz, Austria in June and July 
2017. We tested a convenience series of 28 samples from adult patients, which were 
prospectively collected and tested with the old LFD (and also for GM) between 
November 2012 and September 2016 [6,7,12,13] and subsequently stored at -70°C. 
The samples were selected based on underlying disease (principally hematological 
malignancy, secondarily ICU patients), IPA status according to 2008 EORTC/MSG 
criteria [14], and test result with the old LFD. All 28 samples were selected before the 
first sample was tested with the new LFD. Of the 14 BALF samples from patients 
with probable/proven IPA, 9 were positive with the old LFD (classified here as “true 
positives”), and 5 were negative with the old LFD (classified here as “false 
negatives”). Of the 14 BALF samples from patients without evidence for IPA, 9 were 
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negative with the old LFD (classified here as ‘true negatives’), and 5 patients were 
positive with the old LFD (classified here as ‘false positives’).  
Testing with the new LFD (OLM Diagnostics, Newcastle upon Tyne, United 
Kingdom) was performed in our Microbiology Laboratory. Stored BALF samples 
where thawed, vortexed, and immediately tested without pre-treatment by applying 
100μL of BALF to the test, with results read 15 minutes later, as described previously 
[7]. The interpreters of the LFD test results were blinded to IPA status and results of 
the old LFD, ensuring an unbiased interpretation of the test line results (Figure 1).  
The study protocol was approved by the local ethics committee, Medical University 
Graz, Austria (EC-number 25-221 ex 12/13), and reported to the Austrian Agency for 
Health and Food Safety (Protocol number INS-621000-0478). Results of this study 
are reported according to the STARD statement. 
Performance of the new LFD (including 95% confidence intervals [CI]) was 
compared with that of the old LFD for differentiation between probable/proven IPA 
and no evidence for IPA using descriptive analysis and Fishers exact test. A two-
sided p-value of <0.05 was considered statistically significant. 
 
Results: 
A total of 28 patients (20 females, 8 males, median age 60 years, 23 underlying 
hematological disease, 5 ICU patients) were included in this analysis, of which 14 
fulfilled the criteria for either proven (n=3), or probable IPA (n=11), and 14 patients 
had no evidence for IPA. 17/28 (61%) of patients overall, and 7/14 (50%) of patients 
with probable/proven IPA, were receiving mold-active antifungal prophylaxis/therapy 
at the time of BALF sampling.  
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Characteristics and diagnostic test results for 14 patients with probable/proven IPA 
and those 5 with false positive old LFD results are depicted in Table 1 (details for 
those 9 patients without evidence for IPA and true negative results with the old LFD 
are given in the footnote of the Table). While the new LFD yielded results similar to 
those of the old LFD in 17/28 samples, overall result (i.e., positive versus negative) 
differed in 8/28 samples. In 3/28 BALF samples the results were consistently 
positive, but intensity of the test line differed.  
A total of 10/14 of BALF samples from cases with probable/proven IPA resulted 
positive with the new LFD (sensitivity 71%; 95%CI 42-92%), including 8/9 “true 
positives” and 2/5 “false negatives" with the old LFD. All 14 samples from cases with 
no evidence for IPA  resulted negative with the new LFD (specificity 100%; 95%CI 
77-100%). The specificity of the new LFD was significantly higher compared to the 
old LFD (p=0.04). 
 
Discussion: 
The Aspergillus-specific LFD test has now been formatted for large-scale 
manufacture and CE marking as an IVD for point-of-care diagnosis of IPA. This is 
the first study to clinically evaluate the newly formatted LFD and to compare its 
clinical performance with the old prototype test. We found that the new LFD when 
used with BALF samples was equally sensitive but more specific than the old LFD. 
The clinical sensitivity of 71% and specificity of 100% found in this analysis is 
remarkable considering the BALF selection process, which comprised samples that 
gave false negative or false positive results with the old LFD. In other words, the 
performance of the old LFD with the BALF samples selected for this evaluation (64% 
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sensitivity and 64% specificity), was inferior to the 73% sensitivity and 90% 
specificity published for the old BALF LFD over various patient cohorts, and also 
lower than the published performances of the old LFD in hematological malignancy 
patients (sensitivity 67%, specificity 91%; total n=193 samples), and ICU patients 
(sensitivity 79%, specificity 85%; total n=239 samples) [3].  
The study has limitations of small sample size and sample pre-selection, and so has 
not determined the clinical performance of the new test in a prospectively tested 
cohort. Given that the old LFD was evaluated in a number of prospective multicenter 
studies, the direct comparison to results obtained with the old LFD may be the most 
valuable aspect of this work, but future larger prospective cohort studies are needed 
to confirm our findings. While BALF samples were tested with the new LFD months 
to years after sample collection and testing with the old LFD, it has been shown 
before that the LFD signal remains stable after several years of sample storage at -
70°C [15]. 
In conclusion, the newly formatted LFD may contribute to timely clinical decision 
making regarding initiation and choice of antifungal treatment. Taking into account 
test performance as well as its potential for point-of-care diagnosis, the new LFD 
represents a valuable addition to the currently available diagnostic arsenal for IPA. 
Considering the importance of rapid diagnosis and targeted treatment as major 
predictors of survival in patients with IPA, the potential clinical benefits of this new 
test become evident. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Conflicts of interest 
Martin Hoenigl has received a research grant for an investigator-initiated study from 
Gilead, and speaker's honoraria from MSD, Gilead, and Basilea. Juergen Prattes 
has received consulting fees from Gilead. All other authors no conflict. 
 
Funding 
This work was supported by funds of the Oesterreichische Nationalbank 
(Anniversary Fund, project number 15346) and the Gilead Investigator Initiated 
Study IN-AT-131-1939. This work has also partly been carried out with the K1 
COMET Competence Center CBmed, which is funded by the Federal Ministry of 
Transport, Innovation and Technology (BMVIT); the Federal Ministry of Science, 
Research and Economy (BMWFW); Land Steiermark (Department 12, Business and 
Innovation); the Styrian Business Promotion Agency (SFG); and the Vienna 
Business Agency. The COMET program is executed by the FFG (The Austrian 
Research Promotion Agency, project number 844609). LFD tests used in this study 
were provided by OLM Diagnostics. The funders had no role in study design, data 
collection, analysis, interpretation, decision to publish, in the writing of the 
manuscript, and in the decision to submit the manuscript for publication. 
 
References 
1. Cornely OA, Lass-Florl C, Lagrou K, Arsic-Arsenijevic V, Hoenigl M. Improving 
outcome of fungal diseases - Guiding experts and patients towards excellence. 
Mycoses 2017; 60: 420–425.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
2. Thornton CR. Development of an immunochromatographic lateral-flow device for 
rapid serodiagnosis of invasive aspergillosis. Clin Vaccine Immunol 2008; 15: 1095-
1105.  
3. Heldt S, Hoenigl M. Lateral Flow Assays for the Diagnosis of Invasive 
Aspergillosis: Current Status. Curr Fungal Infect Rep 2017; 11: 45-51.  
4. Eigl S, Prattes J, Lackner M, et al. Multicenter evaluation of a lateral-flow device 
test for diagnosing invasive pulmonary aspergillosis in ICU patients. Crit Care 2015; 
19: 178. 
5. Willinger B, Lackner M, Lass-Florl C, et al. Bronchoalveolar lavage lateral-flow 
device test for invasive pulmonary aspergillosis in solid organ transplant patients: a 
semiprospective multicenter study. Transplantation 2014; 98: 898-902.  
6. Prattes J, Lackner M, Eigl S, et al. Diagnostic accuracy of the Aspergillus-specific 
bronchoalveolar lavage lateral-flow assay in haematological malignancy patients. 
Mycoses 2015; 58: 461-469.  
7. Prattes J, Flick H, Pruller F, et al. Novel tests for diagnosis of invasive 
aspergillosis in patients with underlying respiratory diseases. Am J Respir Crit Care 
Med 2014; 190: 922-929.  
8. Hoenigl M, Prattes J, Spiess B, et al. Performance of galactomannan, beta-d-
glucan, Aspergillus lateral-flow device, conventional culture, and PCR tests with 
bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Clin 
Microbiol 2014; 52: 2039-2045.  
9. Miceli MH, Goggins MI, Chander P, et al. Performance of lateral flow device and 
galactomannan for the detection of Aspergillus species in bronchoalveolar fluid of 
patients at risk for invasive pulmonary aspergillosis. Mycoses 2015; 58: 368-374.  
10. Eigl S, Prattes J, Reinwald M, et al. Influence of mould-active antifungal 
treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid 
lateral-flow device test. Int J Antimicrob Agents 2015; 46: 401-405.  
11. Hoenigl M, Koidl C, Duettmann W, et al. Bronchoalveolar lavage lateral-flow 
device test for invasive pulmonary aspergillosis diagnosis in haematological 
malignancy and solid organ transplant patients. J Infect 2012; 65: 588-591.  
12. Eigl S, Hoenigl M, Spiess B, et al. Galactomannan testing and Aspergillus PCR 
in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive 
aspergillosis. Med Mycol 2017; 55: 528–534.  
13. Orasch T, Prattes J, Faserl K, et al. Bronchoalveolar lavage triacetylfusarinine C 
(TAFC) determination for diagnosis of invasive pulmonary aspergillosis in patients 
with hematological malignancies. J Infect 2017; May 31. Epub ahead of print.  
14. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal 
disease from the European Organization for Research and Treatment of 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of 
Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus 
Group. Clin Infect Dis 2008; 46: 1813-1821.  
15. Prattes J, Koidl C, Eigl S, Krause R, Hoenigl M. Bronchoalveolar lavage fluid 
sample pretreatment with Sputasol((R)) significantly reduces galactomannan levels. 
J Infect 2015; 70: 541-543.  
 
 
 
 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
TABLE 1 Characteristics and Test Results (including those of the New LFD) in Patients with True Positive, False Negative, and False Positive 
Results with the Old LFD for Differentiation of Probable/Proven Invasive Pulmonary Aspergillosis versus No Evidence of IPA. Patients with true 
negative results (n=9) are not displayed.* 
 
Group 
according 
to old LFD 
results and 
IPA Status* 
Pat
ient 
Primary underlying 
disease 
Classifica
tion of 
IPA § 
AF 
therapy/proph
ylaxis at the 
time of 
bronchoscopy 
BALF GM 
ODI 
BALF culture 
for moulds 
BALF 
Aspergillus 
specific 
PCR results 
Old LFD New LFD 
TRUE 
POSITIVES 
1 Plasma cell leukemia probable no 4.85 neg pos +++ +++ 
2 Acute myeloid 
leukemia 
probable yes 4.99 neg pos + ++ 
 
3 Acute myeloid 
leukemia 
probable yes 2.23 neg pos + + 
4 Multiple myeloma probable no 1.88 neg neg ++ + 
5 Chronic lymphoid 
leukemia 
probable yes 19.05 neg n.a. ++ - 
6 ICU COPD probable no 1.06 neg n.a. ++ + 
7 ICU AIDS proven no 17.0 pos pos +++ +++ 
8 ICU septic 
pneumonia 
probable no 5.59 neg pos + + 
9 ICU septic 
pneumonia 
probable no 4.62 neg neg + + 
FALSE 
NEGATIVE
S 
10 Acute myeloid 
leukemia 
proven yes 0.37 neg neg - - 
 
11 Acute lymphoid 
leukemia 
probable yes 2.01 neg neg - + 
12 Acute myeloid 
leukemia 
probable yes 1.59 neg neg - + 
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13 Non-Hodgkin 
lymphoma 
probable yes 1.85 neg neg - - 
14 ICU septic 
pneumonia 
proven no 9.00 pos pos - - 
FALSE 
POSITIVES 
15 Acute myeloid 
leukemia 
no 
evidence 
yes 0.09 neg neg + - 
16 Non-Hodgkin 
lymphoma 
no 
evidence 
yes 0.16 neg neg + - 
17 Multiple myeloma no 
evidence 
yes 0.12 neg n.a. + - 
18 Acute myeloid 
leukemia 
no 
evidence 
no 0.18 neg neg + - 
19 Acute myeloid 
leukemia 
no 
evidence 
yes 0.18 neg n.a. ++ - 
* Patients with true negative results (n=9) not displayed: all 9 had also negative results with new LFD, PCR and culture. 1/9 had a false positive 
BALF GM result (1.04 ODI). With regard to underlying diseases 4/9 had acute myeloid leukemia, 2/9 had acute lymphoid leukemia, each 1/9 
had non-Hodgkin’s lymphoma, multiple myeloma, and severe aplastic anemia). 
§ Defined according to revised EORTC/MSG criteria (14) 
Abbreviations: AIDS = acquired immunodeficiency syndrome; BALF = bronchoalveolar lavage fluid; COPD = chronic obstructive pulmonary 
disease; GM = galactomannan; IPA – invasive pulmonary aspergillosis; LFD = Aspergillus-specific lateral-flow device test; n.a. = not available; 
neg = negative; ODI = optical density index; pos = positive. 
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FIGURE 1 Results with the new Aspergillus-specific lateral-flow device test ranging (from the left to the right) from negative (–) to 
weak positive (+), moderate positive (++) and strong positive (+++)+ 
 
